Q&A: Bio­Marin com­mer­cial chief Jeff Ajer gears up for biggest drug launch to date — with an­oth­er wait­ing in the wings

Is Bio­Marin’s chief com­mer­cial of­fi­cer ready to get off the com­pa­ny’s roller­coast­er ride of the past few years? Not nec­es­sar­i­ly. As CCO Jeff Ajer says it’s ex­pect­ed at Bio­Marin that “drug de­vel­op­ment does not go in a straight line.”

Al­though right now Bio­Marin’s line seems to be a straight line head­ing up. Last week it post­ed pos­i­tive da­ta for its he­mo­phil­ia A gene ther­a­py Roc­ta­vian, bounc­ing back af­ter a sur­prise FDA CRL in 2020 that re­quest­ed more da­ta. It has al­ready filed for Roc­ta­vian’s ap­proval in Eu­rope and plans to sub­mit to the FDA again in the sec­ond quar­ter. Mean­while, in No­vem­ber, it nabbed an FDA nod for Vox­zo­go, the first ap­proved drug to treat chil­dren with achon­dropla­sia, the most com­mon form of dwarfism, fol­low­ing on a sum­mer ap­proval in Eu­rope.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER